Related references
Note: Only part of the references are listed.A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
Monica Galli et al.
ANNALS OF HEMATOLOGY (2010)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Jerome C. Bressi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
Yumin Hu et al.
BLOOD (2010)
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
Bin Zhang et al.
CANCER CELL (2010)
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
Dana Rathkopf et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
Peter M. Wilson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Takashi Watanabe et al.
CANCER SCIENCE (2010)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
Veronica Novotny-Diermayr et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Anne Hansen Ree et al.
LANCET ONCOLOGY (2010)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease
Mark Kilgore et al.
NEUROPSYCHOPHARMACOLOGY (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Emmanuel Raffoux et al.
ONCOTARGET (2010)
Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts
Anne Monks et al.
ANTI-CANCER DRUGS (2009)
Identification of novel regulators of hematopoietic stem cell development through refinement of stem cell localization and expression profiling
Maria I. Mascarenhas et al.
BLOOD (2009)
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Tamer E. Fandy et al.
BLOOD (2009)
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
Melissa J. LaBonte et al.
BMC MEDICAL GENOMICS (2009)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma
A. Rocca et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
Kristie A. Blum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley et al.
CANCER (2009)
Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome on HDAC Inhibitor-Induced Apoptosis
Susan Fotheringham et al.
CANCER CELL (2009)
Biomarkers for predicting clinical responses to HDAC inhibitors
Lindsay Stimson et al.
CANCER LETTERS (2009)
HDAC expression and clinical prognosis in human malignancies
Wilko Weichert
CANCER LETTERS (2009)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
Yutaka Fujiwara et al.
CANCER SCIENCE (2009)
Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes
Zhibin Wang et al.
CELL (2009)
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Jianqing Lin et al.
CLINICAL CANCER RESEARCH (2009)
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Maria Teresa Voso et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2009)
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Adi I. Daud et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2009)
Epigenetic Therapy: Histone Acetylation, DNA Methylation and Anti-Cancer Drug Discovery
A. Ganesan et al.
CURRENT CANCER DRUG TARGETS (2009)
Histone Deacetylase Inhibitors Current Status and Overview of Recent Clinical Trials
Xujun Ma et al.
DRUGS (2009)
A phase 2 study of vorinostat in acute myeloid leukemia
Eric W. Schaefer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2009)
Race to Report: Are Vascular Endothelial Growth Factor Genetic Polymorphisms Associated With Outcome in Advanced Breast Cancer Patients Treated With Paclitaxel Plus Bevacizumab? REPLY
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Luis H. Camacho et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non-Small-Cell Lung Cancer
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
Suresh S. Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Histone deacetylase inhibitor apicidin-mediated drug resistance: Involvement of P-glycoprotein
Yong Kee Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay
Claire Bonfils et al.
CLINICAL CANCER RESEARCH (2008)
Destabilization of ERBB2 transcripts by targeting 3'untranslated region messenger RNA associated HuR and histone deacetylase-6
Gary K. Scott et al.
MOLECULAR CANCER RESEARCH (2008)
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Chromatin-remodelling mechanisms in cancer
Laura Lafon-Hughes et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2008)
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Aleksey G. Kazantsev et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Multicenter phase II trial of the historic deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
Axel Hauschild et al.
MELANOMA RESEARCH (2008)
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice
Elizabeth A. Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Epigenetic regulation of RhoB loss of expression in lung cancer
Julien Mazieres et al.
BMC CANCER (2007)
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies
J. Arts et al.
BRITISH JOURNAL OF CANCER (2007)
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells
Leslie Hodges-Gallagher et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
J. Golay et al.
LEUKEMIA (2007)
Panobinostat.: Histone deacetylase (HDAC) inhibitor, apoptosis inducer, oncolytic
P. Revill et al.
DRUGS OF THE FUTURE (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
MS-275, a potent orally available inhibitor of histone deacetylases - The development of an anticancer agent
Holger Hess-Stumpp et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Assays for pharmacodynamic analysis of histone deacetylase inhibitors
Eun Joo Chung et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors
V Duong et al.
ONCOGENE (2006)
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells
Y Tabe et al.
BLOOD (2006)
Two catalytic domains are required for protein deacetylation
Y Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Chromatin modifier enzymes, the histone code and cancer
H Santos-Rosa et al.
EUROPEAN JOURNAL OF CANCER (2005)
Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance
Y Hirokawa et al.
CANCER BIOLOGY & THERAPY (2005)
Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor α, in response to deacetylase inhibition by valproic acid and trichostatin A
G Reid et al.
ONCOGENE (2005)
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
P Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen
ER Jang et al.
ONCOGENE (2004)
Valproic acid inhibits angiogenesis in vitro and in vivo
M Michaelis et al.
MOLECULAR PHARMACOLOGY (2004)
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
A Burgess et al.
ONCOGENE (2004)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
L Catley et al.
BLOOD (2003)
Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases
B Heitweg et al.
ANALYTICAL BIOCHEMISTRY (2003)
Class II histone deacetylases: versatile regulators
E Verdin et al.
TRENDS IN GENETICS (2003)
Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6
L Pasqualucci et al.
LEUKEMIA & LYMPHOMA (2003)
Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis
L Rössig et al.
CIRCULATION RESEARCH (2002)
Rad23 promotes the targeting of proteolytic substrates to the proteasome
L Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly
L Chen et al.
EMBO REPORTS (2001)
Histone deacetylases and transcriptional therapy with their inhibitors
PP Pandolfi
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
